July 18, 2018 02:10 PM IST
Net Sales are expected to increase by 9.5 percent Y-o-Y (up 4.4 percent Q-o-Q) to Rs. 3,859.1 crore, according to Kotak.
July 12, 2018 12:00 PM IST
The transaction required approval by the South African Competition Commission and is expected to be completed before September 30, 2018.
June 21, 2018 03:34 PM IST
The company has received final approval for its abbreviated new drug application (ANDA) for Testosterone Cypionate injection in the strengths of 100mg/ml and 200mg/ml from the US Food and Drug Administration (USFDA), Cipla said in a filing to BSE.
June 19, 2018 07:05 PM IST
The Mumbai-based firm has received final nod from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Efavirenz tablets in 600mg strength, Cipla said in a statement.
June 16, 2018 12:32 PM IST
Going forward, it expects the Sensex EPS to be Rs 1,870 for FY19 and Rs 2,241 for FY20, an increase of 36 and 20 percent, respectively.
June 14, 2018 11:32 AM IST
The company has received final approval from the United States Food and Drug Administration (USFDA) for its product which is a generic version of Hospira Inc's Isuprel injection, Cipla said in a statement.
June 08, 2018 02:15 PM IST
Cipla expects to start commercialising Basaglar in India by end of this year.
May 31, 2018 03:54 PM IST
Dolat Capital recommended accumulate rating on Cipla with a target price of Rs 585 in its research report dated May 22, 2018.
May 30, 2018 05:30 PM IST
ICICI Direct recommended hold rating on Cipla with a target price of Rs 530 in its research report dated May 23, 2018.
May 28, 2018 05:34 PM IST
JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 600 in its research report dated May 23, 2018.
May 28, 2018 05:31 PM IST
JM Financial is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1440 in its research report dated May 23, 2018.
May 25, 2018 04:28 PM IST
KR Choksey recommended accumulate rating on Cipla with a target price of Rs 607 in its research report dated May 23, 2018.
May 23, 2018 10:33 AM IST
Brokerage houses remained positive on the stock, but slashed target prices following cut in earnings estimates.
May 22, 2018 04:28 PM IST
The operating profit margin expanded 100 basis points to 15.1 percent in Q4 from 14.1 percent in Q4FY17.
May 22, 2018 01:19 PM IST
Cipla is likely to report a net profit of Rs 356.7 crore in the fourth quarter of FY18, according to estimates of Reuters poll of analysts.
May 18, 2018 02:14 PM IST
"Under this agreement, Cipla will get exclusive marketing rights for five years in India for critical limb ischemia due to atherosclerotic peripheral arterial disease (CLI-PAD) with Stempeutics manufacturing and supplying the product to Cipla," the company said in a statement.
May 11, 2018 09:14 AM IST
“Failing to breakout 10,780 may push the Nifty into consolidation,” said Jaydeb Dey, Technical Analyst at Stewart & Mackertich Wealth Management
May 09, 2018 08:35 PM IST
Under the agreement, Cipla is responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI), while MannKind will manufacture and supply the drug
April 25, 2018 02:15 PM IST
The market breadth was in favour of the declines with 553 stocks advancing while 1150 declined and 345 remained unchanged. On the other hand, in the BSE, 864 stocks advanced and 1653 declined and 150 remained unchanged.
April 25, 2018 12:30 PM IST
37 stocks hit fresh 52-week high including Ashok Leyland, Cyient, Indiabulls Ventures, Mahindra & Mahindra, Mindtree, Mphasis and Zydus Wellness among others.
April 18, 2018 09:53 AM IST
The market breadth was in favour of the advances with 900 stocks advancing while 658 declined and 471 remained unchanged. On the other hand, in the BSE, 988 stocks advanced and 705 declined and 89 remained unchanged.
April 17, 2018 02:06 PM IST
"The company is fairly valued at current market price. However, if Q4FY18 results are robust then we can expect a target of Rs 650 by FY19 end," says Akash Jain, Vice-president, Equity Research at Ajcon Global Services.
April 17, 2018 12:39 PM IST
"Its respiratory platform will be the key driver in scaling up its US business trajectory even as its India continues to grow at double-digits. We have a buy rating on the stock with a target of Rs 650," says S Ranganathan, Head of Research at LKP Securities.
April 16, 2018 09:05 PM IST
"The United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from April 2, 2018 till April 13, 2018," Cipla said in a BSE filing.
April 16, 2018 05:58 PM IST
Net Sales are expected to increase by 6.2 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 3,805.3 crore, according to Edelweiss.
